July 2019 tender notification

Tender Closed

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender dated 3 November 2016, 2017/18 Invitation to Tender dated 2 November 2017, and the 2018/19 In

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by:

  • For new listings, by 4pm on the 14 August 2019 or the 5th of the month prior to listing, whichever is earlier
  • For price changes, by 4pm on the 12th of the month prior to the date of subsidy change

PHARMAC cannot list a product (and pharmacies cannot claim) without this information. 

More information about this process and NOPC forms can be found on our website.

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link)  and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1.  Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand
(Supplier)

Date of listing

Date of reference pricing of other listed brands

Sole Subsidised Supply date

Brand (Supplier) affected by reference pricing and delisting

Povidone iodine

Antiseptic soln 10% 15 ml bottle

$0.19
($7.41)

$3.83

Riodine
(Orion)

1 October 2019

n/a

1 March 2020

Betadine
(Sanofi)

Povidone iodine

Antiseptic soln 10%, 100 ml bottle

$1.28
($4.20)

$2.55

Riodine
(Orion)

1 September 2019

n/a

1 February 2020

Betadine
(Sanofi)

Povidone iodine

Antiseptic soln 10%, 500 ml bottle

$6.20

$5.40

Riodine
(Orion)

1 October 2019

1 December 2019

1 March 2020

Betadine
(Sanofi)

Rivastigmine

Patch 4.6 mg per 24 hour; 30 patches

$90.00

$48.75

Generic Partners
(Generic Partners)

1 January 2020

1 March 2020

1 June 2020

Exelon
(Novartis)

Rivastigmine

Patch 9.5 mg per 24 hour; 30 patches

$90.00

$48.75

Generic Partners
(Generic Partners)

1 January 2020

1 March 2020

1 June 2020

Exelon
(Novartis)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Date of subsidy change

Hospital Supply Status date

Povidone iodine

Antiseptic soln 10%, 100 ml bottle

$2.95

$2.55

Riodine
(Orion)

1%

1 September 2019

1 February 2020

1 November 2019 

3. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current pack price

New pack price

Hospital supply brand (Supplier)

DV Limit

Listing date

Hospital Supply Status date

Brand (Supplier) affected by delisting

Povidone iodine

Antiseptic soln 10%, 500 ml bottle

$6.20

$5.40

Riodine
(Orion)

1%

1 October 2019

1 March 2020

Betadine
(Orion)

Rivastigmine

Patch 4.6 mg per 24 hour; 30 patches

$90.00

$48.75

Generic Partners
(Generic Partners)

1%

January 2020

1 March 2020

Exelon
(Novartis)

Rivastigmine

Patch 9.5 mg per 24 hour; 30 patches

$90.00

$48.75

Generic Partners
(Generic Partners)

1%

January 2020

1 March 2020

Exelon
(Novartis)

4. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Povidone iodine

Antiseptic soln 10%, 15 ml bottle

$3.83

Riodine
(Orion)

1%

1 October 2019

1 March 2020

Teicoplanin

Inj 400 mg vial; 1 vial pack

$56.50

Teicoplanin Mylan
(Mylan)

1%

1 February 2020

1 July 2020

2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand
(Supplier)

Date of subsidy change

Sole Subsidised Supply date

Ethinyloestradiol and norethisterone

Tab 35 mcg with norethisterone 1 mg and 7 inert tab; 84 tablet blister pack

$6.62

$6.95

Brevinor 1/28
(Pfizer)

1 October 2019

1 March 2020

Levonorgestrel

Tab 30 mcg; 84 tablet blister pack

$6.62
(16.50)

$16.50

Microlut
(Bayer)

1 February 2020

1 May 2020

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand (Supplier)

Date of listing

Sole Subsidised Supply date

Brand (Supplier) affected by reference pricing and delisting

Metoclopramide hydrochloride

Inj 5 mg per ml, 2 ml ampoule; 10 amp pack

$13.56

$9.50

Pfizer
(Pfizer)

1 October 2019

1 January 2020

Link Healthcare
(Link Healthcare)

Paraffin

White soft; 500 g pot

$3.58
($8.69) or ($7.78)

$4.99

healthE
(Jaychem)

1 November 2019

1 April 2020

PSM (API)
IPW (Multichem)

Paraffin

White soft; 2500 g bucket

$20.20

$19.99

healthE
(Jaychem)

1 November 2019

1 April 2020

IPW
(Multichem)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

7. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Metoclopramide hydrochloride

Inj 5 mg per ml, 2 ml ampoule; 10 amp pack

$13.56

$9.50

Pfizer
(Pfizer)

1%

1 October 2019

1 January 2020

8. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current pack price

New pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Brand (Supplier) affected by delisting

Ketamine

Inj 1 mg per ml, 100 ml bag; 10 bag pack

$27.00 (per 1)

$270.00 (per 10)

Biomed
(Biomed)

1%

1 September 2019

1 February 2020

Biomed (1 pack)
(Biomed)

Ketamine

Inj 10 mg per ml, 10 ml syringe; 5 syringe pack

$14.00 (per 1)

$70.00 (per 5)

Biomed
(Biomed)

1%

1 September 2019

1 February 2020

Biomed (1 pack)
(Biomed)

9. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical name

Presentation;
Pack size and type

New
pack price

Hospital supply brand
(Supplier)

DV
Limit

Listing date

Hospital Supply Status date

Ethinyloestradiol and norethisterone

Tab 35 mcg with norethisterone 1 mg and 7 inert tab; 84 tab blister pack

$6.95

Brevinor 1/28
(Pfizer)

1%

1 October 2019

1 March 2020

Levonorgestrel

Tab 30 mcg; 84 tablet blister pack

$16.50

Microlut
(Bayer)

1%

1 February 2020

1 May 2020

Nimodipine

Tab 30 mg; 100 tab blister pack

$350.00

Nimotop
(Bayer)

1%

1 February 2020

1 July 2020

Nimodipine

Inj 200 mcg per ml, 50 ml vial; 1 vial pack

$67.50

Nimotop
(Bayer)

1%

1 February 2020

1 July 2020

Paraffin

White soft; 500 g pot

$4.99

healthE
(Jaychem)

1%

1 November 2019

1 April 2020

Sucrose

Oral liq 25%; 25 ml bottle

$13.00

Biomed
(Biomed)

1%

1 September 2019

1 February 2020

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

  • the 2016/17 Invitation to Tender, dated 3 November 2016,
  • the 2017/18 Invitation to Tender, dated 2 November 2017, and
  • the 2018/19 Invitation to Tender, dated 1 November 2018

2016/17 invitation to tender

Chemical name

Line item

Amantadine hydrochloride

Cap 100 mg

Benzylpenicillin sodium [Penicillin G]

Inj 3 g

Chlorhexidine with ethanol

Soln 2% with ethanol 70%, non-staining (pink) 100 ml

Chlorhexidine with ethanol

Soln 2% with ethanol 70%, non-staining pink (pack size less than 50 ml)

Chlorhexidine with ethanol

Soln 2% with ethanol 70%, staining (red) 100 ml

Chlorhexidine with ethanol

Soln 2% with ethanol 70%, staining red (pack size less than 50 ml)

Ephedrine

Inj 3 mg per ml, 10 ml prefilled syringe

Hyoscine n-butylbromide

Inj 20 mg, 1 ml

Mebeverine hydrochloride

Tab 135 mg

Tenoxicam

Inj 20 mg

Zinc

Paste (pack size 50 g or less)

2017/18 Invitation to Tender

Chemical name

Line item

Ambrisentan (current access)

Tab 10 mg

Ambrisentan (current access)

Tab 5 mg

Ambrisentan (widened access)

Tab 10 mg

Ambrisentan (widened access)

Tab 5 mg

Budesonide (current access)

Cap 3 mg modified release

Budesonide (widened access)

Cap 3 mg modified release

Bupivacaine hydrochloride

Inj 0.25%, 20 ml sterile pack

Bupivacaine hydrochloride

Inj 0.5%, 10 ml sterile pack

Bupivacaine hydrochloride

Inj 0.5%, 20 ml sterile pack

Calamine

Ltn, BP

Chlorhexidine gluconate

Crm 1% obstetric

Chlorhexidine gluconate

Lotn 1% obstetric

Chlorhexidine gluconate

Soln 4%

Daptomycin

Inj 350 mg – 500 mg

Hydrocortisone butyrate

Lipocream 0.1% (pack size greater than 30 g)

Hydrogen peroxide

Crm 1%

Metaraminol tartrate

Inj 0.5 mg per ml, 20 ml prefilled syringe

Metaraminol tartrate

Inj 1 mg per ml, 10 ml prefilled syringe

Metaraminol tartrate

Inj 10 mg per ml, 1 ml

Mixed salt solution for eye irrigation

Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%,
sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 450 ml - 550 ml

Povidone iodine

Oint 10%

Tobramycin

Solution for inhalation 60 mg per ml, 5 ml

2018/19 Invitation to Tender

Chemical name

Line item

Bupivacaine hydrochloride

Inj 1.25 mg per ml, 200 ml bag

Bupivacaine hydrochloride

Inj 2.5 mg per ml, 20 ml ampoule

Capsaicin

Crm 0.025%

Capsaicin

Crm 0.075%

Gemcitabine hydrochloride

Inj 1 g

Gemcitabine hydrochloride

Inj 200 mg

Lidocaine [Lignocaine] hydrochloride

Inj 1%, 20 ml, sterile pack

Lidocaine [Lignocaine] hydrochloride

Inj 2%, 20 ml, sterile pack

Magnesium sulphate

Inj 0.4 mmol per ml, 250 ml bag

Metronidazole

Inj 5 mg per ml, 100 ml bag

Misoprostol

Tab 200 mcg

Noradrenaline

Inj 0.1 mg per ml, 100 ml bag

Oestradiol

TDDS 100 mcg per day

Oestradiol

TDDS 50 mcg per day

Ondansetron hydrochloride

Inj 2 mg per ml, 2 ml

Ondansetron hydrochloride

Inj 2 mg per ml, 4 ml

Paliperidone

Inj 25 mg syringe

Paliperidone

Inj 50 mg syringe

Paliperidone

Inj 75 mg syringe

Paliperidone

Inj 100 mg syringe

Paliperidone

Inj 150 mg syringe

Piperacillin with tazobactam

Inj 4 g with tazobactam 500 mg

For products included in the 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.